作者

Matthew Royle, Ph.D.

合伙人

Read More

Dr. Manja Epping

合伙人

Read More

Judith Krens

合伙人

Read More

Evelyne Friedel

合伙人

Read More
作者

Matthew Royle, Ph.D.

合伙人

Read More

Dr. Manja Epping

合伙人

Read More

Judith Krens

合伙人

Read More

Evelyne Friedel

合伙人

Read More

2019年9月30日 | 55:41

Biosimilars – Clearing the way for launch

In the third webinar of our series exploring the key differences between US and Europe biosimilars litigation and regulation, our experts discuss strategies for clearing the way to an early launch of a biosimilar.

Many of the top-selling drugs worldwide are biologics, and several companies are seeking to produce biosimilars to compete in these lucrative markets.

There are an increasing number of biologics reaching the end of their primary patent protection, and these companies must navigate the landscape of secondary patent protection in order to launch their biosimilars.

The strategies for doing so differ in the US and Europe, and there are different tools available.

Session 3 of this series focuses on strategic options for securing an early launch of a biosimilar, in particular:

  • devising a strategy to clear the way in Europe
  • so-called Arrow declarations may be available to provide a defence to any pending patent applications
  • Devising a strategy to clear the way in the US.
Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

酒店与休闲

Biologics and biosimilars litigation update

2020年11月25日
Quick read

作者

点击此处了解更多
centrifuge-machine
酒店与休闲

Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents

2020年7月27日
QUICK READ

作者

点击此处了解更多
woman-with-scientific-model
酒店与休闲

Everything biologic and biosimilar in-house counsel need to know about COVID-19

2020年4月29日

作者

点击此处了解更多

相关活动